Estimated Medicare Part D Ocular Drug Savings with a Direct-to-Consumer Pharmacy.
Where this comes from
- Record sourced from PubMed, PMID 42208628.
- Also identified by DOI 10.1016/j.ophtha.2026.05.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Medicare Part D spent $3.8 billion on 50 ophthalmic drugs listed on Mark Cuban Cost Plus Drugs (MCCPD). Using MCCPD pricing could save $2.5 billion annually, with greater competition linked to increased projected savings.